Position in AKBA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$61,566
+$34,152 QoQ
Shares Held
54,006
+437.8% QoQ
Ownership
0.019%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#86
of 170 holders
Holding Since
Mar 2021
9 quarters on record
Voting authority
Sole 29%
Shared 0%
None 71%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026CAPTRUST FINANCIAL ADVISORS holds $43,661,530 across 30 Drug Manufacturers - Specialty & Generic names. AKBA ranks #26 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
121,151 | $8,705,910 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
45,360 | $7,644,974 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
9,855 | $5,339,734 | |
| 4 | VTRS |
Viatris Inc
|
197,717 | $3,139,745 | |
| 5 | HLN |
Haleon plc
|
263,202 | $2,455,674 | |
| 6 | HROW |
Harrow, Inc.
|
56,414 | $2,395,902 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
143,998 | $2,308,287 | |
| 8 | ALKS |
Alkermes plc.
|
42,278 | $2,215,367 |
All Filings in AKBA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $61,566 | 54,006 | Shares | Sole | 2026-08-13 | |
| 2025-09-30 | $27,414 | 10,042 | Shares | Sole | 2025-11-19 | |
| 2025-03-31 | $62,712 | 32,663 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $24,150 | 12,711 | Shares | Sole | 2025-02-14 | |
| 2022-03-31 | $7 | 10 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $22 | 10 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $28 | 10 | Shares | Sole | 2021-11-16 | |
| 2021-06-30 | $1,390 | 367 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $1,563 | 462 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||